文献速递免疫规划慢病防控与筛查

法国男孩人乳头瘤病毒疫苗接种中长期获益与吉兰-巴雷综合征假设风险的模拟研究

Estimation of mid-and long-term benefits and hypothetical risk of Guillain-Barre syndrome after human papillomavirus vaccination among boys in France: A simulation study.
PubMed 文献 · Vaccine · 2021-12-02

研究假设法国11–14岁男孩、成年男性及男男性行为者人群稳定,采用蒙特卡洛模拟量化男孩HPV疫苗接种的中期获益(每年预防的生殖器疣)和长期获益(每年预防的肛门癌病例),并估算假设诱导的吉兰-巴雷综合征病例数。结果显示疫苗覆盖率30%时,每年可预防大量生殖器疣和部分肛门癌,而假设诱导的吉兰-巴雷综合征病例数较少。

要点

  • 疫苗覆盖率30%时,每年预防9310例(95%不确定性区间[7050-11200])15–35岁男性首次生殖器疣。
  • 每年避免15.1[11.7-17.7]至19.2[15.0-22.6]例25–65岁男性肛门癌,取决于疫苗覆盖HPV癌症比例的假设。
  • 11–14岁男孩中,每年假设诱导0.82(0.15-2.3)例吉兰-巴雷综合征。

核心结论

  • 在法国男孩中长期HPV疫苗接种规划所避免的癌症病例数远多于假设诱导的吉兰-巴雷综合征病例数,在一般人群和同性恋人群中均如此。

研究设计与样本

  • 蒙特卡洛模拟研究,假设法国11–14岁男孩、成年男性及男男性行为者人群稳定。

主要发现

  • 疫苗覆盖率30%时,8.72百万15–35岁男性中每年预防9310例(95%不确定性区间[7050-11200])首次生殖器疣。
  • 根据疫苗覆盖HPV癌症比例的不同乐观假设,17.4百万25–65岁男性中每年避免15.1[11.7-17.7]至19.2[15.0-22.6]例肛门癌。
  • 男男性行为者中,每年预防1907例(1944-2291)生殖器疣,避免2.0[0.23-4.5]至2.6[0.29-5.7]例肛门癌。
  • 11–14岁男孩中,每年假设诱导0.82(0.15-2.3)例吉兰-巴雷综合征。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The burden of human papillomavirus (HPV) infection can be substantially reduced through vaccination of girls, and gender-neutral policies are being adopted in many countries to accelerate disease control among women and expand direct benefits to men. Clinical direct benefit of boys HPV vaccination has been established for ano-genital warts and anal cancer. HPV vaccines are considered safe, but an association with Guillain-Barre syndrome has been found in French reimbursement and hospital discharge data. METHODS: We conducted a Monte-Carlo simulation assuming a stable French population of 11- to 14-year-old boys, adult men and men having sex with men. We modelled and quantified the mid-term benefits as the annually prevented ano-genital warts among the 8.72 M men aged 15-35 years and the long-term benefits as the annually prevented anal cancer cases among the 17.4 M men aged 25-65 years. We also estimated the number of Guillain-Barre syndrome cases hypothetically induced by vaccination. RESULTS: With a vaccine coverage of 30%, an annual number of 9310 (95% uncertainty interval [7050-11,200]) first ano-genital warts episodes among the 8.72 M men aged 15-35 years are prevented. According to more or less optimistic hypotheses on the proportion of HPV cancers covered by the vaccine, between 15.1 [11.7-17.7] and 19.2 [15.0-22.6] cases of anal cancer among the 17.4 M men aged 25-65 years would be annually avoided. Among men having sex with men, the corresponding figures were 1907 (1944-2291) for ano-genital warts and between 2.0 [0.23-4.5] and 2.6 [0.29-5.7] for anal cancer. Among 11- to 14-year-old boys, 0.82 (0.15-2.3) Guillain-Barre syndrome cases would be induced annually. INTERPRETATION: A long-term program of HPV vaccination among boys in France would avoid substantially more cancer cases than hypothetically induce Guillain-Barre syndrome cases, in the general and specifically the homosexual population. Additional benefits may arise with the possible vaccine protection against oro-laryngeal and -pharyngeal cancer.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Duong CH, Mueller JE, Tubert-Bitter P, et al. Estimation of mid-and long-term benefits and hypothetical risk of Guillain-Barre syndrome after human papillomavirus vaccination among boys in France: A simulation study. Vaccine. 2021. PMID: 34865876. doi:10.1016/j.vaccine.2021.11.046

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。